Lv W, Jiang X, Zhang Y
Front Cell Neurosci. 2024; 17:1298314.
PMID: 38259501
PMC: 10800710.
DOI: 10.3389/fncel.2023.1298314.
Rudge J
J Alzheimers Dis Rep. 2022; 6(1):129-161.
PMID: 35530118
PMC: 9028744.
DOI: 10.3233/ADR-210299.
Sun M, Sen Gupta A
Semin Thromb Hemost. 2019; 46(5):524-544.
PMID: 31200393
PMC: 10071587.
DOI: 10.1055/s-0039-1692395.
Lee A, Hwang B, Lee M, Lee S, Cho E
Nutr Res Pract. 2016; 10(3):274-81.
PMID: 27247723
PMC: 4880726.
DOI: 10.4162/nrp.2016.10.3.274.
Cho S, Lee S, Yang S, Yun Kim H, Lee M, Kim H
Sci Rep. 2016; 6:20185.
PMID: 26830653
PMC: 4735736.
DOI: 10.1038/srep20185.
Delivery of Polymeric Nanoparticles to Target Vascular Diseases.
Agyare E, Kandimalla K
J Biomol Res Ther. 2015; 3(1).
PMID: 26069867
PMC: 4460796.
DOI: 10.4172/2167-7956.s1-001.
Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.
Mehta D, Short J, Hilmer S, Nicolazzo J
Pharm Res. 2014; 32(3):819-39.
PMID: 25319097
DOI: 10.1007/s11095-014-1522-0.
Pathology associated with AAV mediated expression of beta amyloid or C100 in adult mouse hippocampus and cerebellum.
Drummond E, Muhling J, Martins R, Wijaya L, Ehlert E, Harvey A
PLoS One. 2013; 8(3):e59166.
PMID: 23516609
PMC: 3596293.
DOI: 10.1371/journal.pone.0059166.
Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier.
Banks W
Adv Drug Deliv Rev. 2011; 64(7):629-39.
PMID: 22202501
PMC: 3389492.
DOI: 10.1016/j.addr.2011.12.005.
Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain.
Zhou Q, Fu A, Boado R, Hui E, Lu J, Pardridge W
Mol Pharm. 2010; 8(1):280-5.
PMID: 21141969
PMC: 3034812.
DOI: 10.1021/mp1003515.
Characterization and use of human brain microvascular endothelial cells to examine β-amyloid exchange in the blood-brain barrier.
Bachmeier C, Mullan M, Paris D
Cytotechnology. 2010; 62(6):519-29.
PMID: 20954006
PMC: 2995137.
DOI: 10.1007/s10616-010-9313-x.
Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases.
Chen X, Ghribi O, Geiger J
J Alzheimers Dis. 2010; 20 Suppl 1:S127-41.
PMID: 20164568
PMC: 3086010.
DOI: 10.3233/JAD-2010-1376.
IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey.
Boado R, Lu J, Hui E, Pardridge W
Biotechnol Bioeng. 2009; 105(3):627-35.
PMID: 19816967
PMC: 2838425.
DOI: 10.1002/bit.22576.
Alzheimer's disease drug development and the problem of the blood-brain barrier.
Pardridge W
Alzheimers Dement. 2009; 5(5):427-32.
PMID: 19751922
PMC: 2756824.
DOI: 10.1016/j.jalz.2009.06.003.
Vascular endothelial barrier dysfunction mediated by amyloid-beta proteins.
Nagababu E, Usatyuk P, Enika D, Natarajan V, Rifkind J
J Alzheimers Dis. 2009; 17(4):845-54.
PMID: 19542618
PMC: 2852470.
DOI: 10.3233/JAD-2009-1104.
Soluble aggregates of the amyloid-beta protein selectively stimulate permeability in human brain microvascular endothelial monolayers.
Gonzalez-Velasquez F, Kotarek J, Moss M
J Neurochem. 2008; 107(2):466-77.
PMID: 18702666
PMC: 4406342.
DOI: 10.1111/j.1471-4159.2008.05618.x.
Strategies to improve drug delivery across the blood-brain barrier.
de Boer A, Gaillard P
Clin Pharmacokinet. 2007; 46(7):553-76.
PMID: 17596102
DOI: 10.2165/00003088-200746070-00002.
Alzheimer's disease, brain immune privilege and memory: a hypothesis.
Arshavsky Y
J Neural Transm (Vienna). 2006; 113(11):1697-707.
PMID: 16932992
DOI: 10.1007/s00702-006-0524-4.
Brain endothelial cells as pharmacological targets in brain tumors.
Demeule M, Regina A, Annabi B, Bertrand Y, Bojanowski M, Beliveau R
Mol Neurobiol. 2004; 30(2):157-83.
PMID: 15475625
DOI: 10.1385/MN:30:2:157.